JP2022505604A5 - - Google Patents
Info
- Publication number
- JP2022505604A5 JP2022505604A5 JP2021522004A JP2021522004A JP2022505604A5 JP 2022505604 A5 JP2022505604 A5 JP 2022505604A5 JP 2021522004 A JP2021522004 A JP 2021522004A JP 2021522004 A JP2021522004 A JP 2021522004A JP 2022505604 A5 JP2022505604 A5 JP 2022505604A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- antigen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024019151A JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗npr1抗体およびその使用 |
| JP2025116272A JP2025148445A (ja) | 2018-10-23 | 2025-07-10 | 抗npr1抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749557P | 2018-10-23 | 2018-10-23 | |
| US62/749,557 | 2018-10-23 | ||
| US201862755720P | 2018-11-05 | 2018-11-05 | |
| US62/755,720 | 2018-11-05 | ||
| PCT/US2019/057033 WO2020086406A2 (en) | 2018-10-23 | 2019-10-18 | Anti-npr1 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019151A Division JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗npr1抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505604A JP2022505604A (ja) | 2022-01-14 |
| JP2022505604A5 true JP2022505604A5 (cg-RX-API-DMAC7.html) | 2022-10-24 |
| JP7439076B2 JP7439076B2 (ja) | 2024-02-27 |
Family
ID=68732036
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522004A Active JP7439076B2 (ja) | 2018-10-23 | 2019-10-18 | 抗npr1抗体およびその使用 |
| JP2024019151A Active JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗npr1抗体およびその使用 |
| JP2025116272A Pending JP2025148445A (ja) | 2018-10-23 | 2025-07-10 | 抗npr1抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019151A Active JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗npr1抗体およびその使用 |
| JP2025116272A Pending JP2025148445A (ja) | 2018-10-23 | 2025-07-10 | 抗npr1抗体およびその使用 |
Country Status (16)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3115102A1 (en) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Anti-npr1 antibodies and uses thereof |
| PH12021553101A1 (en) | 2019-06-12 | 2023-10-02 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
| EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| WO2023009529A2 (en) | 2021-07-28 | 2023-02-02 | Trustees Of Boston University | Novel polypeptides and uses thereof |
| US20240327539A1 (en) | 2021-10-11 | 2024-10-03 | Regeneron Pharmaceuticals, Inc. | Methods of effecting a hemodynamic change by administering an anti-npr1 antibody |
| WO2023107957A1 (en) | 2021-12-06 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Antagonist anti-npr1 antibodies and methods of use thereof |
| JP2025510997A (ja) | 2022-03-30 | 2025-04-15 | ノバルティス アーゲー | 抗ナトリウム利尿ペプチド受容体1(npr1)抗体を使用して障害を治療する方法 |
| AU2024287056A1 (en) * | 2023-06-08 | 2025-12-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-npr1 antibody and pharmaceutical use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| US20100310561A1 (en) * | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| EP2370098A4 (en) * | 2008-12-03 | 2013-07-17 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| SG177640A1 (en) * | 2009-07-13 | 2012-02-28 | Genentech Inc | Diagnostic methods and compositions for treatment of cancer |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| US10184942B2 (en) * | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| US9451770B2 (en) | 2012-06-08 | 2016-09-27 | Charles Despres | Method of activating immune response in plants |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| WO2016131943A1 (en) * | 2015-02-20 | 2016-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes |
| WO2017209553A2 (ko) | 2016-06-03 | 2017-12-07 | 사회복지법인 삼성생명공익재단 | 환자 유래 세포를 이용한 항체 스크리닝 방법 |
| WO2018075792A1 (en) * | 2016-10-20 | 2018-04-26 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| US20190135804A1 (en) | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| CA3115102A1 (en) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Anti-npr1 antibodies and uses thereof |
| US12703762B2 (en) | 2018-12-18 | 2026-08-11 | Novartis Ag | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
| PH12021553101A1 (en) | 2019-06-12 | 2023-10-02 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
| EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| WO2023107957A1 (en) | 2021-12-06 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Antagonist anti-npr1 antibodies and methods of use thereof |
-
2019
- 2019-10-18 CA CA3115102A patent/CA3115102A1/en active Pending
- 2019-10-18 WO PCT/US2019/057033 patent/WO2020086406A2/en not_active Ceased
- 2019-10-18 JP JP2021522004A patent/JP7439076B2/ja active Active
- 2019-10-18 MX MX2021004284A patent/MX2021004284A/es unknown
- 2019-10-18 IL IL281297A patent/IL281297B2/en unknown
- 2019-10-18 SG SG11202101037QA patent/SG11202101037QA/en unknown
- 2019-10-18 MY MYPI2021001138A patent/MY205168A/en unknown
- 2019-10-18 EP EP19812875.3A patent/EP3870612A2/en active Pending
- 2019-10-18 KR KR1020217015469A patent/KR20210082207A/ko active Pending
- 2019-10-18 CN CN201980065187.4A patent/CN112805303B/zh active Active
- 2019-10-18 AU AU2019368196A patent/AU2019368196B2/en active Active
- 2019-10-18 US US16/657,000 patent/US11306148B2/en active Active
-
2021
- 2021-02-02 ZA ZA2021/00714A patent/ZA202100714B/en unknown
- 2021-02-03 PH PH12021550255A patent/PH12021550255A1/en unknown
- 2021-04-14 MX MX2024011444A patent/MX2024011444A/es unknown
- 2021-04-15 CL CL2021000942A patent/CL2021000942A1/es unknown
- 2021-05-21 CO CONC2021/0006663A patent/CO2021006663A2/es unknown
-
2022
- 2022-03-10 US US17/692,084 patent/US11820826B2/en active Active
-
2023
- 2023-05-12 CL CL2023001377A patent/CL2023001377A1/es unknown
- 2023-10-11 US US18/485,241 patent/US20240059780A1/en not_active Abandoned
-
2024
- 2024-02-07 CL CL2024000378A patent/CL2024000378A1/es unknown
- 2024-02-13 JP JP2024019151A patent/JP7713051B2/ja active Active
- 2024-05-31 US US18/680,910 patent/US20240309103A1/en active Pending
-
2025
- 2025-07-10 JP JP2025116272A patent/JP2025148445A/ja active Pending